Search

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
GET IN TOUCH
Brochure

Biosimilar Development at Aragen

Download PDF
Over the past decade, the Aragen team has successfully expressed biologics including antibodies, antibody fragments, bispecific antibodies, fusion proteins, hormones, and growth factors. Aragen offers high-expressing cell lines for Biosimilar development.

Cell Line Development for Biosimilars

  • RapTr2022 with HIGH TITRE and REDUCED TIMELINE- Royalty-free CHO DG44 and CHO GS platforms.
  • Our in-house developed CHO DG44 platform can deliver titer >4g/L in 5 months.
  • Aragen also offers a CHO GS platform that can deliver titer >6g/L in 5 months.
  • Our CLD platform uses a chemically defined serum free medium and proof of clonality to support IND filing.
  • Robust upstream and downstream process development (250 ml high-throughput multi-parallel robotic bioreactor
    systems, e.g., Ambr250) to match originator molecule.

Comprehensive analytical and bioassay packages to support clone selection of Biosimilar Cell Line Development: Trastuzumab

  • Generation of clonal cell lines.
  • Evaluation in Fed-batch Shake flask.
  • Validation of shake flask data in AMBR250 and Bioreactor.
  • Analytics to meet the characteristics of Innovator Lot

Adalimumab using Aragen’s proprietary Vector.

  • Stable bulk pool (BP) evaluation reached ~700mg/L.
  • Mini pool (MP) generated, and MP reached up to 4.2g/L.
  • SCC generated from the top two mini-pools and fed-batch shake flask reached up to 6 g/L.
  • Single cell clones show stability over 60 days in respect to cell growth, maintaining high viability and specific productivity.
  • Using Aragen’s optimized process from transfection to single cell clone evaluation completed in 18wks.

Process Development

  • Media adaptation
  • Shake flask fed batch evaluation with dierent media and feed.
  • Scalable and consistent data from shake flask to 1L and 5L Bioreactor in terms of VCD and titer profile

Analytical Characterization

  • Rigorous and Comprehensive Analytics to Support Biologics Discovery and Development
  • Aragen Analytics capabilities include CE-SDS, cIEF, SEC-HPLC/MALS, LC/MS, DLS/SLS, LAL, HIC, HILIC, and SPR/BLI.